|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.71 AUD | -3.71% |
|
+5.06% | +5.91% |
| 01-14 | Australian Shares Flat; Neuren Pharmaceuticals' Nasdaq-Listed Partner Forecasts Rett Syndrome Drug Global Net Sales to Reach $700 Million in 2028 | MT |
| 01-14 | ASX Biggest Gainers | MT |
| Capitalization | 2.59B 1.73B 1.49B 1.38B 1.29B 2.4B 156B 15.92B 6.26B 74.85B 6.5B 6.37B 274B | P/E ratio 2025 * |
147x | P/E ratio 2026 * | 53.2x |
|---|---|---|---|---|---|
| Enterprise value | 2.27B 1.52B 1.3B 1.21B 1.13B 2.1B 137B 13.93B 5.48B 65.5B 5.69B 5.57B 240B | EV / Sales 2025 * |
34.7x | EV / Sales 2026 * | 16.2x |
| Free-Float |
83.48% | Yield 2025 * |
-
| Yield 2026 * | 0.41% |
Last Transcript: Neuren Pharmaceuticals Limited
| 1 day | -3.71% | ||
| 1 week | +5.06% | ||
| Current month | +5.91% | ||
| 1 month | +2.23% | ||
| 3 months | -4.87% | ||
| 6 months | +35.09% | ||
| Current year | +5.91% |
| 1 week | 18.77 |  | 21.04 |
| 1 month | 18.22 | | 21.04 |
| Current year | 18.22 | | 21.04 |
| 1 year | 8.61 | | 22.98 |
| 3 years | 6.72 | | 25.95 |
| 5 years | 1.2 | | 25.95 |
| 10 years | 0.82 | | 25.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 60 | 26/05/2020 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 31/07/2020 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 07/07/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 65 | 04/07/2018 |
Jenny Harry
BRD | Director/Board Member | - | 04/07/2018 |
Jon Pilcher
BRD | Director/Board Member | 60 | 13/06/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.71% | +5.06% | +79.02% | +122.21% | 1.73B | |
| -0.36% | -3.14% | +44.08% | +196.80% | 961B | |
| +2.29% | +5.33% | +50.98% | +26.02% | 527B | |
| +0.52% | -4.94% | +26.40% | +44.46% | 392B | |
| +0.46% | +2.18% | +30.42% | +17.72% | 368B | |
| -0.31% | +1.07% | +34.56% | +22.71% | 299B | |
| +0.37% | +2.53% | +28.77% | +35.28% | 279B | |
| +2.54% | +2.22% | +11.40% | -1.10% | 276B | |
| -1.41% | +0.27% | -38.62% | -22.04% | 262B | |
| +1.44% | -3.71% | +23.16% | +21.07% | 177B | |
| Average | -0.12% | +1.57% | +29.02% | +46.31% | 354.24B | |
| Weighted average by Cap. | +0.04% | +0.05% | +30.03% | +68.11% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 65.43M 43.75M 37.54M 34.95M 32.53M 60.7M 3.95B 402M 158M 1.89B 164M 161M 6.92B | 137M 91.52M 78.54M 73.12M 68.05M 127M 8.26B 841M 331M 3.95B 343M 336M 14.48B |
| Net income | 17.59M 11.76M 10.09M 9.39M 8.74M 16.31M 1.06B 108M 42.49M 508M 44.09M 43.19M 1.86B | 48.04M 32.12M 27.56M 25.66M 23.88M 44.56M 2.9B 295M 116M 1.39B 120M 118M 5.08B |
| Net Debt | -324M -217M -186M -173M -161M -300M -19.55B -1.99B -782M -9.35B -812M -795M -34.26B | -373M -249M -214M -199M -185M -346M -22.49B -2.29B -900M -10.76B -934M -915M -39.42B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 19.71 $ | -3.71% | 581,791 |
| 14/01/26 | 20.47 $ | +6.06% | 670,490 |
| 13/01/26 | 19.30 $ | -0.10% | 211,244 |
| 12/01/26 | 19.32 $ | +0.52% | 198,847 |
| 09/01/26 | 19.22 $ | +2.45% | 217,456 |
Delayed Quote Australian S.E., January 15, 2026 at 05:10 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NEU Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition